FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912821791> ?p ?o ?g. }

• W2912821791 endingPage "S324" @default.
• W2912821791 startingPage "S323" @default.
• W2912821791 abstract "In patients with hematological diseases, there is a different kind of treatment, the autologous stem cell transplant (ASCT) is a potentially useful and beneficial alternative. to perform an ASCT high dose of chemotherapy are required, which would generate severe pancytopenia, and sometimes complicated by febrile neutropenia (FN) and infections, generating a significant increase in morbidity and mortality, in costs and deterioration of patients quality of life. our objective is; to determine the differences regarding the therapeutic response of Pegfilgrastim (PEG) initiated day+1 versus day +5 in patients undergoing an ASCT in the Imbanaco Medical Center. Materials and Methods: retrospective cohort analytical study, comparing a historical cohort of patients who received PEG (6mg/0.6ml) day +5 between January/2013 to March/2015 after ASCT, compared to a cohort that started PEG (6mg/0.6ml) day +1 between Mayo/2015 to June/2016. for the results, evaluation we used the following endpoints: days of recovery of the absolute neutrophil count (ANC), FN, hospital readmissions, day +100 post-transplant mortality. results: the two cohorts day +5 and day+1 with (n=41), (n= 35) patients respectively, the age average was 56.6 years (range 24-72), the most frequent diagnoses were multiple myeloma, Hodgkin's and non-Hodgkin's lymphomas. the recovery of the ANC>500/mm3 was on average on day+11 and +12 figure.1 (HR: 2.39; (p=>0.05) in the PEG+1 and PEG+5 groups, respectively; the incidence of FN was 50%(p=0.026) in both cohorts. when compared regarding hospital readmissions group day+5 presented 7.3% (3/41) vs 0% (0/35) of group day+1. no cases of mortality 100 days post-transplant were reporting in both groups. any report of infections during the inpatient therapy in both groups. conclusions: administering PEG on day+1 shortened the ANC > 500 /mm3 recovery day by at least one day, maintaining the same efficacy of the therapy with respect a similar incidence of FN, infections and 100 days post-transplant mortality associated with transplantation with PEG day +5. the final results of the analysis of this study will be present at the congress. In patients with hematological diseases, there is a different kind of treatment, the autologous stem cell transplant (ASCT) is a potentially useful and beneficial alternative. to perform an ASCT high dose of chemotherapy are required, which would generate severe pancytopenia, and sometimes complicated by febrile neutropenia (FN) and infections, generating a significant increase in morbidity and mortality, in costs and deterioration of patients quality of life. our objective is; to determine the differences regarding the therapeutic response of Pegfilgrastim (PEG) initiated day+1 versus day +5 in patients undergoing an ASCT in the Imbanaco Medical Center. Materials and Methods: retrospective cohort analytical study, comparing a historical cohort of patients who received PEG (6mg/0.6ml) day +5 between January/2013 to March/2015 after ASCT, compared to a cohort that started PEG (6mg/0.6ml) day +1 between Mayo/2015 to June/2016. for the results, evaluation we used the following endpoints: days of recovery of the absolute neutrophil count (ANC), FN, hospital readmissions, day +100 post-transplant mortality. results: the two cohorts day +5 and day+1 with (n=41), (n= 35) patients respectively, the age average was 56.6 years (range 24-72), the most frequent diagnoses were multiple myeloma, Hodgkin's and non-Hodgkin's lymphomas. the recovery of the ANC>500/mm3 was on average on day+11 and +12 figure.1 (HR: 2.39; (p=>0.05) in the PEG+1 and PEG+5 groups, respectively; the incidence of FN was 50%(p=0.026) in both cohorts. when compared regarding hospital readmissions group day+5 presented 7.3% (3/41) vs 0% (0/35) of group day+1. no cases of mortality 100 days post-transplant were reporting in both groups. any report of infections during the inpatient therapy in both groups. conclusions: administering PEG on day+1 shortened the ANC > 500 /mm3 recovery day by at least one day, maintaining the same efficacy of the therapy with respect a similar incidence of FN, infections and 100 days post-transplant mortality associated with transplantation with PEG day +5. the final results of the analysis of this study will be present at the congress. Figure 1." @default.
• W2912821791 created "2019-02-21" @default.
• W2912821791 creator A5013376132 @default.
• W2912821791 creator A5039099407 @default.
• W2912821791 creator A5041953511 @default.
• W2912821791 creator A5047320398 @default.
• W2912821791 creator A5047748515 @default.
• W2912821791 creator A5050882003 @default.
• W2912821791 creator A5081041058 @default.
• W2912821791 creator A5083962362 @default.
• W2912821791 date "2019-03-01" @default.
• W2912821791 modified "2023-10-14" @default.
• W2912821791 title "Pegfilgrastim Started First Day Vs Fifth Day Post-Autologous Stem Cell Transplant" @default.
• W2912821791 doi "https://doi.org/10.1016/j.bbmt.2018.12.523" @default.
• W2912821791 hasPublicationYear "2019" @default.
• W2912821791 type Work @default.
• W2912821791 sameAs 2912821791 @default.
• W2912821791 citedByCount "0" @default.
• W2912821791 crossrefType "journal-article" @default.
• W2912821791 hasAuthorship W2912821791A5013376132 @default.
• W2912821791 hasAuthorship W2912821791A5039099407 @default.
• W2912821791 hasAuthorship W2912821791A5041953511 @default.
• W2912821791 hasAuthorship W2912821791A5047320398 @default.
• W2912821791 hasAuthorship W2912821791A5047748515 @default.
• W2912821791 hasAuthorship W2912821791A5050882003 @default.
• W2912821791 hasAuthorship W2912821791A5081041058 @default.
• W2912821791 hasAuthorship W2912821791A5083962362 @default.
• W2912821791 hasBestOaLocation W29128217911 @default.
• W2912821791 hasConcept C120665830 @default.
• W2912821791 hasConcept C121332964 @default.
• W2912821791 hasConcept C126322002 @default.
• W2912821791 hasConcept C141071460 @default.
• W2912821791 hasConcept C167135981 @default.
• W2912821791 hasConcept C2776364478 @default.
• W2912821791 hasConcept C2776694085 @default.
• W2912821791 hasConcept C2777063308 @default.
• W2912821791 hasConcept C2778658803 @default.
• W2912821791 hasConcept C2778850193 @default.
• W2912821791 hasConcept C2779050716 @default.
• W2912821791 hasConcept C2779382419 @default.
• W2912821791 hasConcept C2780007613 @default.
• W2912821791 hasConcept C61511704 @default.
• W2912821791 hasConcept C71924100 @default.
• W2912821791 hasConcept C72563966 @default.
• W2912821791 hasConcept C74133956 @default.
• W2912821791 hasConceptScore W2912821791C120665830 @default.
• W2912821791 hasConceptScore W2912821791C121332964 @default.
• W2912821791 hasConceptScore W2912821791C126322002 @default.
• W2912821791 hasConceptScore W2912821791C141071460 @default.
• W2912821791 hasConceptScore W2912821791C167135981 @default.
• W2912821791 hasConceptScore W2912821791C2776364478 @default.
• W2912821791 hasConceptScore W2912821791C2776694085 @default.
• W2912821791 hasConceptScore W2912821791C2777063308 @default.
• W2912821791 hasConceptScore W2912821791C2778658803 @default.
• W2912821791 hasConceptScore W2912821791C2778850193 @default.
• W2912821791 hasConceptScore W2912821791C2779050716 @default.
• W2912821791 hasConceptScore W2912821791C2779382419 @default.
• W2912821791 hasConceptScore W2912821791C2780007613 @default.
• W2912821791 hasConceptScore W2912821791C61511704 @default.
• W2912821791 hasConceptScore W2912821791C71924100 @default.
• W2912821791 hasConceptScore W2912821791C72563966 @default.
• W2912821791 hasConceptScore W2912821791C74133956 @default.
• W2912821791 hasIssue "3" @default.
• W2912821791 hasLocation W29128217911 @default.
• W2912821791 hasOpenAccess W2912821791 @default.
• W2912821791 hasPrimaryLocation W29128217911 @default.
• W2912821791 hasRelatedWork W1996623943 @default.
• W2912821791 hasRelatedWork W2033106246 @default.
• W2912821791 hasRelatedWork W2067849462 @default.
• W2912821791 hasRelatedWork W2280462110 @default.
• W2912821791 hasRelatedWork W2528447728 @default.
• W2912821791 hasRelatedWork W2561198757 @default.
• W2912821791 hasRelatedWork W2576424445 @default.
• W2912821791 hasRelatedWork W2804325849 @default.
• W2912821791 hasRelatedWork W2912821791 @default.
• W2912821791 hasRelatedWork W2951723430 @default.
• W2912821791 hasVolume "25" @default.
• W2912821791 isParatext "false" @default.
• W2912821791 isRetracted "false" @default.
• W2912821791 magId "2912821791" @default.
• W2912821791 workType "article" @default.